Cargando…
Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects
INTRODUCTION: Indoleamine 2,3-dioxygenase (IDO) was a potential tumor immunotherapy target. IDO inhibitors showed inconsistent results in clinical trials, but no preclinical comparative study was reported. The purpose of this study was to evaluate the differences of representative IDO inhibitors (PC...
Autores principales: | Jiang, Xue, Li, Xiaopeng, Zheng, Shuang, Du, Guangying, Ma, Jinbo, Zhang, Liming, Wang, Hongbo, Tian, Jingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517983/ https://www.ncbi.nlm.nih.gov/pubmed/32962460 http://dx.doi.org/10.1177/2058738420950584 |
Ejemplares similares
-
PCC0208009 enhances the anti-tumor effects of temozolomide through
direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase
in glioma models
por: Sun, Shanyue, et al.
Publicado: (2018) -
Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
por: Meng, Xiangjing, et al.
Publicado: (2017) -
Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface
por: Kudo, Yoshiki, et al.
Publicado: (2020) -
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
por: Zulfiqar, Bilal, et al.
Publicado: (2017) -
Identification and Characterization of a Novel Dual Inhibitor of
Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase
por: Yoshioka, Saeko, et al.
Publicado: (2022)